Recombinant Plasma Proteins Market, Global Outlook and Forecast 2022-2028

March 2022 | 64 pages | ID: RD81026104B5EN
Market Monitor Global

Abstracts

For almost 50 years, the fractionation of human plasma has been the sole possible source of a wide range of therapeutic proteins--such as coagulation factors, anticoagulants, immunoglobulins, and albumin--essential to the treatment of serious congenital or acquired bleeding or immunological diseases. In the last 20 years, the application of recombinant technologies to mammalian cell cultures has made possible--although with some limitations in productivity, costs, and immunogenic risks-

This report contains market size and forecasts of Recombinant Plasma Proteins in Global, including the following market information:

Global Recombinant Plasma Proteins Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Recombinant Plasma Proteins market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Chinese Hamster Ovary (CHO) Cell Line Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Recombinant Plasma Proteins include CSL Limited, Shire (Takeda Pharmaceutical Company Limited), Octapharma, Novo Nordisk, Bayer, Bioverativ Therapeutics, Inc. (Sanofi), Aptevo Therapeutics, Pharming Group and Pfizer. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Recombinant Plasma Proteins companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Recombinant Plasma Proteins Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Recombinant Plasma Proteins Market Segment Percentages, by Type, 2021 (%)

• Chinese Hamster Ovary (CHO) Cell Line
• Baby Hamster Kidney (BHK) Cell Line
• Human Embryonic Kidney (HEK) Cell Line
• Others

Global Recombinant Plasma Proteins Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Recombinant Plasma Proteins Market Segment Percentages, by Application, 2021 (%)

• Hemophilia A
• Hemophilia B
• Von Willebrand Disease
• Others

Global Recombinant Plasma Proteins Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Recombinant Plasma Proteins Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Recombinant Plasma Proteins revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Recombinant Plasma Proteins revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• CSL Limited
• Shire (Takeda Pharmaceutical Company Limited)
• Octapharma
• Novo Nordisk
• Bayer
• Bioverativ Therapeutics, Inc. (Sanofi)
• Aptevo Therapeutics
• Pharming Group
• Pfizer

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Recombinant Plasma Proteins Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Recombinant Plasma Proteins Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL RECOMBINANT PLASMA PROTEINS OVERALL MARKET SIZE

2.1 Global Recombinant Plasma Proteins Market Size: 2021 VS 2028
2.2 Global Recombinant Plasma Proteins Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Recombinant Plasma Proteins Players in Global Market
3.2 Top Global Recombinant Plasma Proteins Companies Ranked by Revenue
3.3 Global Recombinant Plasma Proteins Revenue by Companies
3.4 Top 3 and Top 5 Recombinant Plasma Proteins Companies in Global Market, by Revenue in 2021
3.5 Global Companies Recombinant Plasma Proteins Product Type
3.6 Tier 1, Tier 2 and Tier 3 Recombinant Plasma Proteins Players in Global Market
  3.6.1 List of Global Tier 1 Recombinant Plasma Proteins Companies
  3.6.2 List of Global Tier 2 and Tier 3 Recombinant Plasma Proteins Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Recombinant Plasma Proteins Market Size Markets, 2021 & 2028
  4.1.2 Chinese Hamster Ovary (CHO) Cell Line
  4.1.3 Baby Hamster Kidney (BHK) Cell Line
  4.1.4 Human Embryonic Kidney (HEK) Cell Line
  4.1.5 Others
4.2 By Type - Global Recombinant Plasma Proteins Revenue & Forecasts
  4.2.1 By Type - Global Recombinant Plasma Proteins Revenue, 2017-2022
  4.2.2 By Type - Global Recombinant Plasma Proteins Revenue, 2023-2028
  4.2.3 By Type - Global Recombinant Plasma Proteins Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Recombinant Plasma Proteins Market Size, 2021 & 2028
  5.1.2 Hemophilia A
  5.1.3 Hemophilia B
  5.1.4 Von Willebrand Disease
  5.1.5 Others
5.2 By Application - Global Recombinant Plasma Proteins Revenue & Forecasts
  5.2.1 By Application - Global Recombinant Plasma Proteins Revenue, 2017-2022
  5.2.2 By Application - Global Recombinant Plasma Proteins Revenue, 2023-2028
  5.2.3 By Application - Global Recombinant Plasma Proteins Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Recombinant Plasma Proteins Market Size, 2021 & 2028
6.2 By Region - Global Recombinant Plasma Proteins Revenue & Forecasts
  6.2.1 By Region - Global Recombinant Plasma Proteins Revenue, 2017-2022
  6.2.2 By Region - Global Recombinant Plasma Proteins Revenue, 2023-2028
  6.2.3 By Region - Global Recombinant Plasma Proteins Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Recombinant Plasma Proteins Revenue, 2017-2028
  6.3.2 US Recombinant Plasma Proteins Market Size, 2017-2028
  6.3.3 Canada Recombinant Plasma Proteins Market Size, 2017-2028
  6.3.4 Mexico Recombinant Plasma Proteins Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Recombinant Plasma Proteins Revenue, 2017-2028
  6.4.2 Germany Recombinant Plasma Proteins Market Size, 2017-2028
  6.4.3 France Recombinant Plasma Proteins Market Size, 2017-2028
  6.4.4 U.K. Recombinant Plasma Proteins Market Size, 2017-2028
  6.4.5 Italy Recombinant Plasma Proteins Market Size, 2017-2028
  6.4.6 Russia Recombinant Plasma Proteins Market Size, 2017-2028
  6.4.7 Nordic Countries Recombinant Plasma Proteins Market Size, 2017-2028
  6.4.8 Benelux Recombinant Plasma Proteins Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Recombinant Plasma Proteins Revenue, 2017-2028
  6.5.2 China Recombinant Plasma Proteins Market Size, 2017-2028
  6.5.3 Japan Recombinant Plasma Proteins Market Size, 2017-2028
  6.5.4 South Korea Recombinant Plasma Proteins Market Size, 2017-2028
  6.5.5 Southeast Asia Recombinant Plasma Proteins Market Size, 2017-2028
  6.5.6 India Recombinant Plasma Proteins Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Recombinant Plasma Proteins Revenue, 2017-2028
  6.6.2 Brazil Recombinant Plasma Proteins Market Size, 2017-2028
  6.6.3 Argentina Recombinant Plasma Proteins Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Recombinant Plasma Proteins Revenue, 2017-2028
  6.7.2 Turkey Recombinant Plasma Proteins Market Size, 2017-2028
  6.7.3 Israel Recombinant Plasma Proteins Market Size, 2017-2028
  6.7.4 Saudi Arabia Recombinant Plasma Proteins Market Size, 2017-2028
  6.7.5 UAE Recombinant Plasma Proteins Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 CSL Limited
  7.1.1 CSL Limited Corporate Summary
  7.1.2 CSL Limited Business Overview
  7.1.3 CSL Limited Recombinant Plasma Proteins Major Product Offerings
  7.1.4 CSL Limited Recombinant Plasma Proteins Revenue in Global Market (2017-2022)
  7.1.5 CSL Limited Key News
7.2 Shire (Takeda Pharmaceutical Company Limited)
  7.2.1 Shire (Takeda Pharmaceutical Company Limited) Corporate Summary
  7.2.2 Shire (Takeda Pharmaceutical Company Limited) Business Overview
  7.2.3 Shire (Takeda Pharmaceutical Company Limited) Recombinant Plasma Proteins Major Product Offerings
  7.2.4 Shire (Takeda Pharmaceutical Company Limited) Recombinant Plasma Proteins Revenue in Global Market (2017-2022)
  7.2.5 Shire (Takeda Pharmaceutical Company Limited) Key News
7.3 Octapharma
  7.3.1 Octapharma Corporate Summary
  7.3.2 Octapharma Business Overview
  7.3.3 Octapharma Recombinant Plasma Proteins Major Product Offerings
  7.3.4 Octapharma Recombinant Plasma Proteins Revenue in Global Market (2017-2022)
  7.3.5 Octapharma Key News
7.4 Novo Nordisk
  7.4.1 Novo Nordisk Corporate Summary
  7.4.2 Novo Nordisk Business Overview
  7.4.3 Novo Nordisk Recombinant Plasma Proteins Major Product Offerings
  7.4.4 Novo Nordisk Recombinant Plasma Proteins Revenue in Global Market (2017-2022)
  7.4.5 Novo Nordisk Key News
7.5 Bayer
  7.5.1 Bayer Corporate Summary
  7.5.2 Bayer Business Overview
  7.5.3 Bayer Recombinant Plasma Proteins Major Product Offerings
  7.5.4 Bayer Recombinant Plasma Proteins Revenue in Global Market (2017-2022)
  7.5.5 Bayer Key News
7.6 Bioverativ Therapeutics, Inc. (Sanofi)
  7.6.1 Bioverativ Therapeutics, Inc. (Sanofi) Corporate Summary
  7.6.2 Bioverativ Therapeutics, Inc. (Sanofi) Business Overview
  7.6.3 Bioverativ Therapeutics, Inc. (Sanofi) Recombinant Plasma Proteins Major Product Offerings
  7.6.4 Bioverativ Therapeutics, Inc. (Sanofi) Recombinant Plasma Proteins Revenue in Global Market (2017-2022)
  7.6.5 Bioverativ Therapeutics, Inc. (Sanofi) Key News
7.7 Aptevo Therapeutics
  7.7.1 Aptevo Therapeutics Corporate Summary
  7.7.2 Aptevo Therapeutics Business Overview
  7.7.3 Aptevo Therapeutics Recombinant Plasma Proteins Major Product Offerings
  7.7.4 Aptevo Therapeutics Recombinant Plasma Proteins Revenue in Global Market (2017-2022)
  7.7.5 Aptevo Therapeutics Key News
7.8 Pharming Group
  7.8.1 Pharming Group Corporate Summary
  7.8.2 Pharming Group Business Overview
  7.8.3 Pharming Group Recombinant Plasma Proteins Major Product Offerings
  7.8.4 Pharming Group Recombinant Plasma Proteins Revenue in Global Market (2017-2022)
  7.8.5 Pharming Group Key News
7.9 Pfizer
  7.9.1 Pfizer Corporate Summary
  7.9.2 Pfizer Business Overview
  7.9.3 Pfizer Recombinant Plasma Proteins Major Product Offerings
  7.9.4 Pfizer Recombinant Plasma Proteins Revenue in Global Market (2017-2022)
  7.9.5 Pfizer Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Recombinant Plasma Proteins Market Opportunities & Trends in Global Market
Table 2. Recombinant Plasma Proteins Market Drivers in Global Market
Table 3. Recombinant Plasma Proteins Market Restraints in Global Market
Table 4. Key Players of Recombinant Plasma Proteins in Global Market
Table 5. Top Recombinant Plasma Proteins Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Recombinant Plasma Proteins Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Recombinant Plasma Proteins Revenue Share by Companies, 2017-2022
Table 8. Global Companies Recombinant Plasma Proteins Product Type
Table 9. List of Global Tier 1 Recombinant Plasma Proteins Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Recombinant Plasma Proteins Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Recombinant Plasma Proteins Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Recombinant Plasma Proteins Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Recombinant Plasma Proteins Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Recombinant Plasma Proteins Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Recombinant Plasma Proteins Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Recombinant Plasma Proteins Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Recombinant Plasma Proteins Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Recombinant Plasma Proteins Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Recombinant Plasma Proteins Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Recombinant Plasma Proteins Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Recombinant Plasma Proteins Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Recombinant Plasma Proteins Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Recombinant Plasma Proteins Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Recombinant Plasma Proteins Revenue, (US$, Mn), 2023-2028
Table 30. CSL Limited Corporate Summary
Table 31. CSL Limited Recombinant Plasma Proteins Product Offerings
Table 32. CSL Limited Recombinant Plasma Proteins Revenue (US$, Mn), (2017-2022)
Table 33. Shire (Takeda Pharmaceutical Company Limited) Corporate Summary
Table 34. Shire (Takeda Pharmaceutical Company Limited) Recombinant Plasma Proteins Product Offerings
Table 35. Shire (Takeda Pharmaceutical Company Limited) Recombinant Plasma Proteins Revenue (US$, Mn), (2017-2022)
Table 36. Octapharma Corporate Summary
Table 37. Octapharma Recombinant Plasma Proteins Product Offerings
Table 38. Octapharma Recombinant Plasma Proteins Revenue (US$, Mn), (2017-2022)
Table 39. Novo Nordisk Corporate Summary
Table 40. Novo Nordisk Recombinant Plasma Proteins Product Offerings
Table 41. Novo Nordisk Recombinant Plasma Proteins Revenue (US$, Mn), (2017-2022)
Table 42. Bayer Corporate Summary
Table 43. Bayer Recombinant Plasma Proteins Product Offerings
Table 44. Bayer Recombinant Plasma Proteins Revenue (US$, Mn), (2017-2022)
Table 45. Bioverativ Therapeutics, Inc. (Sanofi) Corporate Summary
Table 46. Bioverativ Therapeutics, Inc. (Sanofi) Recombinant Plasma Proteins Product Offerings
Table 47. Bioverativ Therapeutics, Inc. (Sanofi) Recombinant Plasma Proteins Revenue (US$, Mn), (2017-2022)
Table 48. Aptevo Therapeutics Corporate Summary
Table 49. Aptevo Therapeutics Recombinant Plasma Proteins Product Offerings
Table 50. Aptevo Therapeutics Recombinant Plasma Proteins Revenue (US$, Mn), (2017-2022)
Table 51. Pharming Group Corporate Summary
Table 52. Pharming Group Recombinant Plasma Proteins Product Offerings
Table 53. Pharming Group Recombinant Plasma Proteins Revenue (US$, Mn), (2017-2022)
Table 54. Pfizer Corporate Summary
Table 55. Pfizer Recombinant Plasma Proteins Product Offerings
Table 56. Pfizer Recombinant Plasma Proteins Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Recombinant Plasma Proteins Segment by Type in 2021
Figure 2. Recombinant Plasma Proteins Segment by Application in 2021
Figure 3. Global Recombinant Plasma Proteins Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Recombinant Plasma Proteins Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Recombinant Plasma Proteins Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Recombinant Plasma Proteins Revenue in 2021
Figure 8. By Type - Global Recombinant Plasma Proteins Revenue Market Share, 2017-2028
Figure 9. By Application - Global Recombinant Plasma Proteins Revenue Market Share, 2017-2028
Figure 10. By Region - Global Recombinant Plasma Proteins Revenue Market Share, 2017-2028
Figure 11. By Country - North America Recombinant Plasma Proteins Revenue Market Share, 2017-2028
Figure 12. US Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Recombinant Plasma Proteins Revenue Market Share, 2017-2028
Figure 16. Germany Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2028
Figure 17. France Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Recombinant Plasma Proteins Revenue Market Share, 2017-2028
Figure 24. China Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2028
Figure 28. India Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Recombinant Plasma Proteins Revenue Market Share, 2017-2028
Figure 30. Brazil Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Recombinant Plasma Proteins Revenue Market Share, 2017-2028
Figure 33. Turkey Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Recombinant Plasma Proteins Revenue, (US$, Mn), 2017-2028
Figure 37. CSL Limited Recombinant Plasma Proteins Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Shire (Takeda Pharmaceutical Company Limited) Recombinant Plasma Proteins Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Octapharma Recombinant Plasma Proteins Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Novo Nordisk Recombinant Plasma Proteins Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Bayer Recombinant Plasma Proteins Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Bioverativ Therapeutics, Inc. (Sanofi) Recombinant Plasma Proteins Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Aptevo Therapeutics Recombinant Plasma Proteins Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Pharming Group Recombinant Plasma Proteins Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Pfizer Recombinant Plasma Proteins Revenue Year Over Year Growth (US$, Mn) & (2017-2022)